Foundayo side effects: what the label reports
The short answer
The most common Foundayo side effects in the label's trials were nausea (26% to 35% across the three doses, 10% on placebo), constipation (20% to 27%), diarrhea (21% to 25%) and vomiting (13% to 24%). Those figures come from two pooled trials in 3155 adults with obesity or overweight, treated once daily for up to 72 weeks. Tell your prescriber about dehydration or severe abdominal pain.
Key takeaways
- Nausea, constipation, diarrhea and vomiting lead the Foundayo table, and most stomach reactions weren't severe.
- Foundayo carries a boxed warning, the strongest kind the FDA requires, about thyroid C-cell tumors.
- It must not be used with a personal or family history of medullary thyroid carcinoma or with MEN 2.
- For an allergic reaction, the label says to promptly seek medical attention and stop Foundayo.
- Tell your prescriber about dehydration, severe abdominal pain, signs of low blood sugar or a planned procedure with sedation.
On this page
- What are the most common side effects of Foundayo?
- How severe are stomach side effects on Foundayo?
- Does Foundayo cause hair loss or a faster heart rate?
- What does the boxed warning say, and what are the serious side effects?
- How many people stop Foundayo because of side effects?
- When to call your prescriber
- Frequently asked questions
- Sources
How often it was reported in the label's trials
| Reaction | Placebon=1576 | 5.5 mgn=1051 | 9 mgn=1055 | 17.2 mgn=1049 |
|---|---|---|---|---|
| Nausea | 10% | 26% | 34% | 35% |
| Constipation | 9% | 20% | 27% | 24% |
| Diarrhea | 11% | 21% | 23% | 25% |
| Vomiting | 4% | 13% | 21% | 24% |
| Dyspepsia | 4% | 12% | 16% | 13% |
| Abdominal pain | 7% | 13% | 14% | 14% |
| Headache | 7% | 8% | 9% | 9% |
| Abdominal distension | 3% | 7% | 9% | 8% |
| Fatigue | 4% | 6% | 7% | 9% |
| Eructation | 1% | 6% | 8% | 8% |
| Gastroesophageal reflux disease | 2% | 6% | 6% | 7% |
| Flatulence | 2% | 5% | 6% | 6% |
| Hair loss | 2% | 4% | 4% | 5% |
Foundayo: Gastrointestinal adverse reactions
In a pool of Trials 1 and 2, gastrointestinal adverse reactions occurred more frequently among patients treated with once daily FOUNDAYO 5.5 mg (60%), 9 mg (68%), and 17.2 mg (69%) than placebo (37%). More patients treated with once daily FOUNDAYO 5.5 mg (3%), 9 mg (6%), and 17.2 mg (6%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.7%).
Foundayo: Severity of gastrointestinal reactions
Of the FOUNDAYO-treated patients who reported GI adverse reactions, 60%, 36%, and 4% reported mild or moderate or severe adverse reactions, respectively. The incidence of nausea, vomiting, and diarrhea was higher during the FOUNDAYO dosage escalation period and decreased over time.
Foundayo: Hypoglycemia
In Trial 2, a trial of patients with type 2 diabetes and BMI ≥27 kg/m², hypoglycemia (glucose <54 mg/dL) was reported in 2% of FOUNDAYO-treated patients versus 0.2% of placebo-treated patients.
Foundayo: Hypoglycemia with a sulfonylurea
In this trial, 7% of patients taking FOUNDAYO in combination with sulfonylurea reported hypoglycemia compared with 0.5% of patients not taking sulfonylurea.
Foundayo: Hypoglycemia in adults without type 2 diabetes
In Trial 1, a trial of FOUNDAYO in adults with BMI ≥27 kg/m² without type 2 diabetes, there was no systematic capturing of hypoglycemia, but glucose <54 mg/dL was reported in 0.6% of FOUNDAYO-treated patients and no placebo-treated patients.
Foundayo: Hair loss
Hair loss adverse reactions in FOUNDAYO-treated patients were associated with weight reduction. In a pool of Trials 1 and 2, hair loss was reported more frequently in female than male patients in the FOUNDAYO (7% female versus 0.9% male) and placebo (3% female versus 0.7% male) treatment groups.
Foundayo: Tachycardia and heart rate increase
In a pool of Trials 1 and 2, tachycardia (tachycardia, heart rate increased, and sinus tachycardia) was reported in 3% of patients treated with FOUNDAYO and 0.9% receiving placebo. Treatment with FOUNDAYO resulted in a mean increase in heart rate of 4 to 5 beats per minute from baseline compared to 0.5 beat per minute with placebo.
Foundayo: Acute gallbladder disease
In a pool of Trials 1 and 2, cholelithiasis was reported in 1% of FOUNDAYO-treated patients and 0.7% of placebo-treated patients, and acute cholecystitis was reported in 0.4% of FOUNDAYO-treated patients and 0.3% of placebo-treated patients.
Foundayo: Acute pancreatitis
In a pool of Trials 1 and 2, 6 events of acute pancreatitis were confirmed by adjudication in 6 FOUNDAYO-treated patients (0.14 patients per 100 years of exposure) versus 2 events in 1 placebo-treated patient (0.04 patients per 100 years of exposure).
Foundayo: Acute kidney injury
In a pool of Trials 1 and 2, acute kidney injury was reported in 0.2% of FOUNDAYO-treated patients compared to 0.05% of placebo-treated patients.
Foundayo: Hypotension
In a pool of Trials 1 and 2, hypotension occurred more frequently among patients taking FOUNDAYO (2%) than patients taking placebo (0.5%). Hypotension was more frequently seen in FOUNDAYO-treated patients on concomitant antihypertensive therapy (4%) compared to FOUNDAYO-treated patients not on antihypertensive therapy (1%).
Foundayo: Dizziness
In a pool of Trials 1 and 2, dizziness was reported in 4% of FOUNDAYO-treated patients and 3% of placebo-treated patients.
Foundayo: Dysgeusia
In a pool of Trials 1 and 2, dysgeusia was reported in 0.9% of FOUNDAYO-treated patients and 0.3% of placebo-treated patients.
Foundayo: Dysesthesia
In a pool of Trials 1 and 2, dysesthesia was reported in 0.3% and 1% of patients treated with FOUNDAYO 9 mg, and 17.2 mg, respectively, and 0.1% of patients receiving placebo. No patients taking FOUNDAYO 5.5 mg reported dysesthesia.
Foundayo: Hypersensitivity reactions
In a pool of Trials 1 and 2, hypersensitivity reactions, including anaphylactic reaction, occurred in 0.5% of FOUNDAYO-treated patients compared to 0.3% of placebo-treated patients.
Foundayo: Amylase and lipase increase
In a pool of Trials 1 and 2, treatment with FOUNDAYO resulted in mean increases from baseline in serum pancreatic amylase concentrations of 16% to 20% and serum lipase concentrations of 26% to 31%, compared to mean increases from baseline in serum pancreatic amylase of 3% and serum lipase of 4% in placebo-treated patients.
Warnings on the Foundayo label
Risk of Thyroid C-Cell Tumors
Medicines that act on the GLP-1 receptor have caused thyroid C-cell tumors in rodents; orforglipron did not, but it is not active in rats or mice, and the relevance to people is unknown.
In products with GLP-1 receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents [see Nonclinical Toxicology (13.1)].
Acute Pancreatitis
Inflammation of the pancreas has been reported with Foundayo, and it should be stopped if pancreatitis is suspected.
Acute pancreatitis has been reported in patients treated with FOUNDAYO. Fatal and non-fatal hemorrhagic or necrotizing pancreatitis have been observed in patients treated with GLP-1 receptor agonists [see Adverse Reactions (6)].
Severe Gastrointestinal Reactions
Foundayo can cause stomach and bowel side effects that are sometimes severe, and it is not recommended for people with severe gastroparesis.
Use of FOUNDAYO has been associated with gastrointestinal adverse reactions, sometimes severe. In clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients treated with orforglipron (approximately 3%) than patients who received placebo (1%).
Acute Kidney Injury Due to Volume Depletion
Dehydration from nausea, vomiting or diarrhea has led to acute kidney injury in some patients.
There have been reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists or FOUNDAYO. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions (6)].
Hypoglycemia
Foundayo lowers blood sugar and can cause low blood sugar, with higher risk when used with insulin or a sulfonylurea.
FOUNDAYO lowers blood glucose and can cause hypoglycemia.
Hypersensitivity Reactions
Serious allergic reactions such as anaphylaxis and angioedema have been reported with GLP-1 medicines.
Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists [see Adverse Reactions (6.2)]. If hypersensitivity reactions occur, advise the patient to promptly seek medical attention and discontinue use of FOUNDAYO.
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes
Rapid improvement in blood sugar has been linked to temporary worsening of diabetic retinopathy, and Foundayo was not studied in patients needing acute treatment for it.
Temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control. FOUNDAYO has not been studied in patients with diabetic retinopathy and/or macular edema requiring acute treatment.
Acute Gallbladder Disease
Foundayo is associated with more gallbladder problems such as gallstones and gallbladder inflammation.
Treatment with FOUNDAYO and GLP-1 receptor agonists is associated with an increased occurrence of acute gallbladder disease.
Pulmonary Aspiration During General Anesthesia or Deep Sedation
Because Foundayo slows stomach emptying, there have been rare reports with GLP-1 medicines of stomach contents entering the lungs during anesthesia or deep sedation.
FOUNDAYO delays gastric emptying [see Clinical Pharmacology (12.2)]. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.
If a side effect has you worried, tell your prescriber about nausea, vomiting or diarrhea that leaves you dehydrated, and about severe abdominal pain. For an allergic reaction, the label says to promptly seek medical attention and stop Foundayo. Leave any other dose changes to your prescriber.
Foundayo (orforglipron) is a tablet taken once daily, and its side-effect table is led by the same stomach and bowel reactions seen with the injectable medicines of this class. The figures come from a pool of two placebo-controlled weight management trials (Trials 1 and 2). They included 3155 adults with obesity or overweight, with or without type 2 diabetes, who took Foundayo once daily for up to 72 weeks. A placebo group gets an inactive treatment instead of the medicine.
What are the most common side effects of Foundayo?
The label’s table lists reactions reported by at least 5% of Foundayo patients. Each line shows 5.5 mg, 9 mg and 17.2 mg, then placebo.
- Nausea: 26%, 34% and 35%, with 10% on placebo.
- Constipation: 20%, 27% and 24%, with 9% on placebo.
- Diarrhea: 21%, 23% and 25%, with 11% on placebo.
- Vomiting: 13%, 21% and 24%, with 4% on placebo.
- Dyspepsia (indigestion): 12%, 16% and 13%, with 4% on placebo.
- Abdominal pain: 13%, 14% and 14%, with 7% on placebo.
- Headache: 8%, 9% and 9%, with 7% on placebo.
- Fatigue: 6%, 7% and 9%, with 4% on placebo.
How severe are stomach side effects on Foundayo?
They’re frequent, and most weren’t severe. Counted together, gastrointestinal (stomach and bowel) reactions were reported by 60% of patients at 5.5 mg, 68% at 9 mg and 69% at 17.2 mg, against 37% on placebo.
The label also grades them by severity. Of the Foundayo patients who reported a gastrointestinal reaction, 60% reported mild reactions, 36% moderate and 4% severe. The label adds that the incidence of nausea, vomiting and diarrhea “was higher during the FOUNDAYO dosage escalation period and decreased over time.” Dosage escalation is the weeks when the dose is being raised.
In its warning on severe gastrointestinal reactions, the label puts them at approximately 3% of patients on orforglipron and 1% on placebo. It says Foundayo is not recommended in patients with severe gastroparesis (a stomach that empties very slowly).
Does Foundayo cause hair loss or a faster heart rate?
Hair loss was reported by 4%, 4% and 5% of patients across the three doses, against 2% on placebo. It was more frequent in women than men in both groups: 7% against 0.9% on Foundayo, and 3% against 0.7% on placebo. The label says these reactions “were associated with weight reduction.” There’s more on the hair loss page.
Heart rate. Tachycardia, a fast heart rate, was reported in 3% of Foundayo patients and 0.9% on placebo. The mean increase in heart rate was 4 to 5 beats per minute, compared with 0.5 beat per minute on placebo.
Low blood pressure occurred in 2% of patients on Foundayo and 0.5% on placebo, and more often in those also taking blood pressure medicine (4%) than in those who were not (1%).
What does the boxed warning say, and what are the serious side effects?
A boxed warning is the strongest kind the FDA requires, set apart in a box on the label. Foundayo’s reads differently from the others in this class. It says that products with GLP-1 receptor agonist activity have produced thyroid C-cell tumors in rats and mice, and then: “Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents.” The relevance to people isn’t known. Foundayo is contraindicated, meaning it must not be used, in patients with a personal or family history of medullary thyroid carcinoma (MTC) or with MEN 2 (Multiple Endocrine Neoplasia syndrome type 2).
The other warnings, with the pooled trial figures:
- Acute pancreatitis (inflammation of the pancreas): 6 confirmed events in 6 Foundayo patients, and 2 events in 1 placebo patient.
- Acute kidney injury: 0.2% on Foundayo and 0.05% on placebo, mostly linked to dehydration from nausea, vomiting or diarrhea.
- Gallbladder disease: gallstones in 1% on Foundayo and 0.7% on placebo.
- Low blood sugar: in the trial of patients with type 2 diabetes, glucose below 54 mg/dL was reported in 2% on Foundayo and 0.2% on placebo. Among patients also taking a sulfonylurea, a type of diabetes pill, 7% reported hypoglycemia (low blood sugar).
- Allergic reactions, including anaphylactic reaction (a sudden and severe whole-body reaction): 0.5% on Foundayo and 0.3% on placebo.
- Diabetic retinopathy (eye damage from diabetes) and pulmonary aspiration (stomach contents entering the lungs) during general anesthesia or deep sedation.
The safety guide explains each warning.
How many people stop Foundayo because of side effects?
Across both trials, 8% of Foundayo patients permanently stopped treatment because of side effects (6% at 5.5 mg, 9% at 9 mg and 10% at 17.2 mg), compared with 3% on placebo. Gastrointestinal reactions were the main reason, accounting for 5% of Foundayo patients.
When to call your prescriber
The label is direct on one point. If a hypersensitivity (allergic) reaction occurs, patients should be advised “to promptly seek medical attention and discontinue use of FOUNDAYO.”
Beyond that, the warnings show what a prescriber needs to hear about:
- Nausea, vomiting or diarrhea that leaves you dehydrated.
- Severe abdominal pain. The label says Foundayo should be stopped if pancreatitis is suspected.
- Signs of low blood sugar, above all if you take insulin or a sulfonylurea.
- A planned surgery or procedure with general anesthesia or deep sedation.
Leave dose changes to your prescriber. The Foundayo guide covers how the tablet is taken, and the side effects guide compares each reaction across medicines.
Frequently asked questions
What are the most common side effects of Foundayo?
Nausea, constipation, diarrhea and vomiting. In the label's two pooled trials, 26% of patients at 5.5 mg, 34% at 9 mg and 35% at 17.2 mg reported nausea, against 10% on placebo. Constipation was reported by 20%, 27% and 24%, diarrhea by 21%, 23% and 25%, and vomiting by 13%, 21% and 24%.
How long do Foundayo side effects last?
The label says the incidence of nausea, vomiting and diarrhea was higher during the Foundayo dosage escalation period, the weeks when the dose is being raised, and decreased over time. That describes the whole trial group, not what you personally should expect. If a reaction doesn't ease, raise it with your prescriber.
Does Foundayo cause hair loss?
Hair loss is in the label's table: 4% of patients at 5.5 mg, 4% at 9 mg and 5% at 17.2 mg, against 2% on placebo. Women reported it more often than men (7% against 0.9% on Foundayo). The label says hair loss was associated with weight reduction.
Is Foundayo safe?
The label doesn't answer with a yes or a no. Its boxed warning, the strongest kind the FDA requires, says medicines with GLP-1 receptor activity have caused thyroid C-cell tumors in rodents, and that orforglipron is not pharmacologically active in rats or mice and did not produce tumors in them. Foundayo must not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2.
What are the serious side effects of Foundayo?
The label's warnings cover acute pancreatitis, severe stomach and bowel reactions, acute kidney injury after dehydration, low blood sugar, serious allergic reactions, diabetic retinopathy complications (eye damage from diabetes), acute gallbladder disease and pulmonary aspiration during anesthesia or deep sedation. Severe stomach and bowel reactions were reported by approximately 3% of patients on orforglipron and 1% on placebo.
Sources (3)
- 1.FDA label (DailyMed): Foundayo prescribing information, section 4
“FOUNDAYO is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].”
- 2.FDA label (DailyMed): Foundayo prescribing information, section 5.3
“FOUNDAYO is not recommended in patients with severe gastroparesis.”
- 3.
